Invest before our planned Nasdaq listing under MXRX

Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

NASDAQ Here We Come. Meet MXRX.

We’re planning a direct listing on the Nasdaq, and we’ve already reserved the ticker symbol "MXRX.” This is a rare opportunity to invest before it happens.

Sign Up For Company Updates

Your Email
Submission received! Check your inbox for the Med-X updates.
Oops! Something went wrong while submitting the form.

 Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

Leading Organic Trade Organization Lists Nature-Cide All-Purpose Commercial Concentrate as Allowed for the Use in Accordance with the National Organic Program (NOP) Standards for use Cases in Certified Organic Food Processing and Handling Facilities

LOS ANGELES – November 7, 2024 -- Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced that the Company’s Nature-Cide All-Purpose Commercial Concentrate Insecticide has secured the widely coveted designation as an OMRI® Listed product.

The Organic Materials Review Institute (OMRI) is a nonprofit organization that provides independent reviews of products intended for several use cases including use in certified organic food processing  and handling. To be listed by OMRI, a pesticide product must meet strict standards for organic processing outlined by USDA National Organic Program (NOP). With the designation as an OMRI Listed Product, Nature-Cide All-Purpose Commercial Concentrate, is now one of 12 botanical pesticide products that is allowed for use in certified organic food processing and handling facilities meeting the USDA National Organic Program standards.

A white bottle with a labelDescription automatically generated

Nature-Cide All-Purpose Commercial Concentrate has been designated as “Allowed With Restrictions” carrying the following statement: For use as a pesticide in post-harvest handling of raw agricultural commodities only in conjunction with the facility pest management practices provided for in paragraphs 205.271(a) and (b) and only if those practices are not effective to prevent or control pests alone. 

Matthew Mills, Chief Executive Officer of Med-X, stated: “After several years of requests from industry professionals, we are incredibly humbled to have achieved the coveted OMRI listing for one of our flagship Nature-Cide products. Pest management professionals operating in USDA certified organic facilities rely on OMRI to assure that the products they use meet the strict OMRI listing requirements, knowing that they use ingredients and formulations that are allowed under the NOP standards.

“This OMRI listing opens up a whole new market for Med-X, providing a safer and highly effective solution to pest management professionals working with a limited set of permissible tools to do their job, all while concurrently making it easier for pest management professionals to find the product and have the information and confidence that it can be used in organic facilities when needed.   

“The pest control solutions for organic use market was valued at $2.4 billion in 2023 and taken together, we continue to see significant global sales momentum with our partner network for our Nature-Cide product line, addressing an urgent need for all-natural products that can be safely used in organic or sensitive industries such as agriculture and hospitality,” concluded Mills.

About Med-X, Inc.

Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at www.medx-rx.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.

 

Investor Relations Contact

Lucas Zimmerman

Managing Director

MZ Group - MZ North America

+1 (262) 357-2918

MXRX@mzgroup.us  

www.mzgroup.us  

‍

FAQs

Where can I find more information on Med-X?

You can review all of Med-X’s SEC Filings, including the offering circular for the Regulation A+ offering, here.

What is the offering Price?

The offering price is [$X] per [security type] and the minimum investment amount for this round is [Min Investment Amount].

How and when can I access the subscription document and invest?

Click “Invest Now” anywhere on this site, or follow this link [insert link here]. You will be directed to view the subscription agreement and complete an investment. Payment is accepted via [insert payment options].

What payment options are available?

Investors can purchase shares via credit card, bank-to-bank payments, or express wires (reconciled in real-time). An administrative fee of $[  ] will be applied to all investments. (if applicable).

Do I need to be an accredited investor?

This offering is open to both accredited and non-accredited investors. If you are a non-accredited investor, please note that you cannot invest more than 10% of the greater of your annual income or net worth.

What is an accredited investor? 

According to the SEC, an individual accredited investor can be defined as the following:  

An accredited investor, in the context of a natural person, includes anyone who: 

  • earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR 
  • has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), OR 
  • holds in good standing a Series 7, 65 or 82 license. 

Additionally, an accredited investor as an entity can be defined as the following: 

  1. A trust is considered to be an accredited investor if its assets exceed $5 million, it is not created to purchase the securities and it is directed by a sophisticated person; or 
  1. An entity is an accredited investor if its investment exceeds $5 million and it is not created to purchase securities. 
  1. An entity in which all equity owners are accredited investors. 
Why did my payment get rejected? What can I do to resolve this?

If your credit card payment was declined, please call your credit card provider to pre-authorize the transaction. Additionally, if your bank-to-bank transfer via ACH has failed, it is recommended that you contact your bank for more information.

How can I change the email address associated with my account?

To change your email address, please navigate to the top-right corner of your Dashboard. Within your profile settings, you can change the email address associated with your account. If you would like to merge investments to a pre-existing account, under a different email address, please contact info@dealmaker.tech for assistance. Please specify the applicable email addresses to be changed. For investor security, you will be asked to verify that you have access to the applicable accounts.

How can I invest as a trust or corporation?

You can specify whether you are investing as an individual, or as a corporation/trust/custodial. Upon selecting any of the non-individual options, you will be prompted to enter relevant information and populate your subscription agreement accordingly.

What happens after I complete the online investment process?

1) Funding Processed:  

Your investment funding status will update upon receipt of your funds. If paying by bank-to-bank transfer, your payment will initially appear as pending, and will either clear or fail within five business days. If paying by wire domestically, your wire should be reconciled within one business day. International wires vary. Once funds are received, it can take approximately [1-2 weeks] *customize per issuer to process your investment completely. 

2) Identity Processed: 

In some instances, we may reach out to you requesting additional information in order to verify your identity & finish processing your investment, which may increase the overall processing time. 

3) Subscription Confirmation: 

Once your investment has been fully processed and confirmed, you will receive a notification when your subscription agreement has been accepted.Subsequently, you will receive a digital confirmation of the security holdings.If a [number of weeks] pass by and you do not receive any information from us, please email us at [company email address] We may still require additional information. We recommend you check your spam folder first for any email communications! 

‍

Will I receive a paper share certificate?

Please note that if your securities are being distributed through the DealMaker platform, you will receive a digital certificate or DRS statement from the issuer’s transfer agent, uploaded to your investment portal. No paper share certificates are distributed via DealMaker.  

‍

For further information regarding DRS statement distribution, please contact our investor support team at: [insert email address/phone number] or our transfer agent at: [insert transfer agent contact].  

‍

When will this raise end?

Currently, the deadline for the offering is [INSERT DATE]. We may close the offering earlier than the deadline in the offering materials, for example, if we reach the target offering amount prior to the deadline.

I would like to speak to someone about my investment, who can I contact? 

For more information regarding your investment in this offering, please contact our investor support team at: investorrelations@medx-rx.com

I haven’t found the answer to my question. Where can I look next? 

You can search the DealMaker knowledge base for more information here, or contact investor support at investorrelations@medx-rx.com

Can I transfer my shares? 

Yes. Securities sold in a Regulation A+ offering are not considered “restricted securities” under Securities Act Rule 144. As a result, sales of securities by persons who are not affiliates of the issuer are not subject to any transfer restrictions.

‍

Investors need to check with a brokerage account representative to determine whether their provider will allow for the securities to be (i) directly deposited to a brokerage account or (ii) transferred into such account at a later day. The policies may vary between different providers. 

‍

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.

Submission received! Check your inbox for the Med-X updates.
Oops! Something went wrong while submitting the form.